Table 1 New HCv therapies in the pipeline
Drug name | Company | Target / Active drug | Study phase |
|---|---|---|---|
NS3/4A protease inhibitors | Â | Â | Â |
Ciluprevir (BILN 2061) | Boehringer Ingelheim | Active site / macrocyclic | Stopped |
Boceprevir (SCH503034) | Merck | Active site / linear | Phase 3 |
Telaprevir (VX-950) | vertex | Active site / linear | Phase 3 |
Danoprevir (RG7227) | Roche | Active site / macrocyclic | Phase 2 |
TMC435 | Tibotec / Medivir | Active site / macrocyclic | Phase 2 |
Vaniprevir (MK-7009) | Merck | Active site / macrocyclic | Phase 2 |
BI 201335 | Boehringer Ingelheim | Active site / linear | Phase 2 |
BMS-650032 | Bristol-Myers Squibb | Active site | Phase 2 |
GS-9256 | Gilead | Active site | Phase 2 |
ABT-450 | Abbott / Enanta | Active site | Phase 2 |
Narlaprevir (SCH900518) | Merck | Active site / linear | On hold |
PHX1766 | Phenomix | Active site | Phase 1 |
ACH-1625 | Achillion | Active site / linear | Phase 2 |
IDX320 | Idenix | Active site / macrocyclic | On hold |
MK-5172 | Merck | Active site / macrocyclic | Phase 1 |
VX-985 | Vertex | Active site | Phase 1 |
GS-9451 | Gilead | Active site | Phase 1 |
Nucleos(t)ide NS5B polymerase inhibitors | Â | Â | |
Valopicitabine (NM-283) | Idenix / Novartis | Active site / NM-107 | Stopped |
RG7128 | Roche / Pharmasset | Active site / PSI-6130 | Phase 2 |
IDX184 | Idenix | Active site | On hold |
R1626 | Roche | Active site / R1479 | Stopped |
PSI-7977 | Pharmasset | Active site | Phase 2 |
PSI-938 | Pharmasset | Active site | Phase 1 |
INX-189 | Inhibitex | Active site | Phase 1 |
Non-nucleoside NS5B polymerase inhibitors | Â | Â | |
BILB 1941 | Boehringer Ingelheim | NNI site 1 / thumb 1 | Stopped |
BI 207127 | Boehringer Ingelheim | NNI site 1 / thumb 1 | Phase 2 |
MK-3281 | Merck | NNI site 1 / thumb 1 | Stopped |
Filibuvir (PF-00868554) | Pfizer | NNI site 2 / thumb 2 | Phase 2 |
VX-916 | Vertex | NNI site 2 / thumb 2 | On hold |
VX-222 | Vertex | NNI site 2 / thumb 2 | Phase 2 |
VX-759 | Vertex | NNI site 2 / thumb 2 | Phase 1 |
ANA598 | Anadys | NNI site 3 / palm 1 | Phase 2 |
ABT-333 | Abbott | NNI site 3 / palm 1 | Phase 2 |
ABT-072 | Abbott | NNI site 3 / palm 1 | Phase 2 |
Nesbuvir (HCV-796) | ViroPharma / Wyeth | NNI site 4 / palm 2 | Stopped |
Tegobuvir (GS-9190) | Gilead | NNI site 4 / palm 2 | Phase 2 |
IDX375 | Idenix | NNI site 4 / palm 2 | Phase 1 |
NS5A inhibitors | Â | Â | Â |
BMS-790052 | Bristol-Myers Squibb | NS5A domain 1 inhibitor | Phase 2 |
BMS-824393 | Bristol-Myers Squibb | NS5A inhibitor | Phase 1 |
AZD7295 | AstraZeneca | NS5A inhibitor | Phase 1 |
PPI-461 | Presidio | NS5A inhibitor | Phase 1 |
Indirect inhibitors / unknown mechanism of action | Â | Â | |
NIM811 | Novartis | Cyclophilin inhibitor | Stopped |
SCY-635 | Scynexis | Cyclophilin inhibitor | Phase 1 |
Alisporivir (Debio-025) | Debiopharm / Novartis | Cyclophilin inhibitor | Phase 2 |
Alinia (nitazoxanide) | Romark | PKR induction ? | Phase 2 |
Celgosivir | BioWest | Alpha-glucosidase inhibitor | Stopped |
New formulations of current therapies | Â | Â | |
Taribavirin | Valeant | / ribavirin | Phase 2 |
Locteron (BLX-883) | Biolex | Interferon receptor type 1 | Phase 2 |
PEG-rIL-29 (peginterferon lambda) | ZymoGenetics / BMS | Interferon receptor type 3 | Phase 2 |
Joulferon (albinterferon alfa-2b) | HGS / Novartis | interferon receptor type 1 | Stopped |